-
Mashup Score: 1
Digital twins critical for digital transformation of the aerospace-defense industry…
Source: www.globenewswire.comCategories: General Medicine NewsTweet
-
Mashup Score: 4Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA - 10 day(s) ago
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation –…
Source: www.globenewswire.comCategories: General Medicine NewsTweet-
🚨 News 🚨 A new drug application has been submitted to @US_FDA for ziftomenib, a once-daily, oral menin inhibitor, for the treatment of adult patients with NPM1-mutated R/R AML. Notification from the FDA is expected by Q2 2025. https://t.co/Bk0yYb0bSa #AMLsm #MedNews #Leusm https://t.co/8TzLmlUAga
-
-
Mashup Score: 0Konica Minolta Healthcare Launches the Next-Generation Exa Platform Featuring Embedded Advanced Visualization Functionality - 11 day(s) ago
WAYNE, N.J., April 03, 2025 (GLOBE NEWSWIRE) — Konica Minolta Healthcare Americas, Inc. has launched the next-generation of the Exa® Platform with the…
Source: www.globenewswire.comCategories: General Medicine NewsTweet-
.@KonicaMinoltaMI Healthcare Launches the Next-Generation #Exa Platform Featuring Embedded #AdvancedVisualization Functionality | #imaginginformatics #imagingIT https://t.co/Amvc2Sbd1v
-
-
Mashup Score: 39New research from The Lundquist Institute finds ketogenic diet-induced high cholesterol does not predict heart disease - 12 day(s) ago
A one-year prospective study found that very high cholesterol in 100 otherwise metabolically healthy individuals on a ketogenic diet for an average of 5…
Source: www.globenewswire.comCategories: General Medicine NewsTweet-
Press release through @globenewswire via Lundquist on our groundbreaking study 👇👇👇 https://t.co/0h5OeYZkbe
-
-
Mashup Score: 1Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - 18 day(s) ago
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete…
Source: www.globenewswire.comCategories: General Medicine NewsTweet-
Wonderful to see that #tovecimig is active in #cholangiocarcinoma, hitting primary ORR endpoint (17 vs 5%)! Potentially a future standard option for patients… but toxicity/PFS/OS will be important to evaluate as well: https://t.co/71PdRBXllI
-
-
Mashup Score: 0
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one…
Source: www.globenewswire.comCategories: General Medicine NewsTweet-
https://t.co/athiq5XlHH
-
-
Mashup Score: 3Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline - 1 month(s) ago
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter…
Source: www.globenewswire.comCategories: General Medicine News, Hem/OncsTweet-
RT @bradloncar: Sanofi bought a bispecific (CD20) myeloid cell engager for $600M up front. https://t.co/23B8lSJRHD
-
-
Mashup Score: 1
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and…
Source: www.globenewswire.comCategories: General Medicine News, Hem/OncsTweet-
JUST IN: @BeamTx Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation! What a feat ! https://t.co/UJOr56NyfI
-
-
Mashup Score: 7Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston - 1 month(s) ago
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data…
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet-
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston https://t.co/3hUYezPQAd @Roche @genentech https://t.co/4hB6I8QK6T
-
-
Mashup Score: 0Enlitic and GE HealthCare to Collaborate to Redefine Imaging Data Migration and Cloud Solutions for Enterprise Imaging - 2 month(s) ago
Enlitic, Laitek, and GE HealthCare collaborate on AI-driven imaging data migration solutions….
Source: www.globenewswire.comCategories: General Medicine News, General HCPsTweet-
.@Enlitic and @GEHealthCare to Collaborate to Redefine Imaging Data Migration and #Cloud Solutions for #EnterpriseImaging | #radiology https://t.co/ExfbcyqHZH
-
RT @shyamvaran: Digital Twin Consortium Publishes Digital Twin Research & Technology Gap Whitepaper - https://t.co/nkjNecGolK